投资者可于 2024 年 12 月 03 日(星期二) 至 12 月 09 日(星期一) )16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 shinva@16 3.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600587 证券简称：新华医疗 公告编号：临 2024-040 山东新华医疗器械股份有限公司 重要内容提示： 会议召开时间：2024 年 12 月 10 日(星期二) 上午 11:00-12:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.s seinfo.com/） 会议召开方式：上证路演中心网络互动 山东新华医疗器械股份有限公司（以下简称"公司"）已于 2024 年 10 月 30 日发布公司 2024 第三季度报告，为便于广大投资者更全面深入地了解公司 2024 第三季度经营成果、财务状况，公司计划于 2024 年 1 ...

Group 1 - Shenzhen Huachuang Zhixin Medical Technology Co., Ltd. has been established with a registered capital of 30 million yuan [1] - The legal representative of the company is Yang Jinbin [1] - The business scope includes medical research and experimental development, production and sales of Class I medical devices, research and development of mechanical equipment, and manufacturing of experimental analysis instruments [1] Group 2 - The company is wholly owned by Shandong High-tech Medical Device Innovation Center Co., Ltd. [1] - Shandong High-tech Medical Device Innovation Center Co., Ltd. is jointly held by Xinhua Medical and Zibo Industrial Technology Research Institute Co., Ltd. [1]

山东新华医疗器械股份有限公司 关于公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）于近 日收到山东省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体 情况如下： 一、医疗器械注册证的具体情况 1、产品名称：蒸汽灭菌器 证券代码：600587 证券简称：新华医疗 公告编号：临 2024-039 3、注册人名称：山东新华医疗器械股份有限公司 4、注册人住所：山东省淄博市高新技术产业开发区新华医疗科技园 5、生产地址：淄博市周村区新华大道 2009 号 6、结构及组成：蒸汽灭菌器主要由柜体、柜门、消毒车、搬运车、加热系统 （仅限自带蒸汽发生器的设备）、管路系统和控制系统组成。 7、型号、规格：MK-A：MK-A448、MK-A667、MK-A669、MK-A6911、MK- A6914、MK-A6918、MK-A61115、MK-A61118、MK-A61125 2、注册证编号：鲁械注准 20242110941 MK- ...

Investment Rating - The report maintains a "Recommended" investment rating for Xinhua Medical (600587) with a target price of 22 CNY, while the current price is 17.64 CNY [2]. Core Views - The company's Q3 revenue remained flat at 74.23 billion CNY, with a net profit of 6.17 billion CNY, reflecting a 6.63% increase. The net profit margin improved to 5.93% from 5.35% in the previous year [2][3]. - The medical device sector is under pressure due to a decline in bidding amounts for infection control projects compared to the same period last year, leading to delayed procurement demand from hospitals [2]. - The company's gross margin slightly decreased to 25.53%, attributed to a slowdown in revenue growth from the high-margin medical device segment [2]. - The report forecasts a steady increase in net profit for the years 2024 to 2026, with expected figures of 10.4 billion CNY, 12.8 billion CNY, and 14.1 billion CNY respectively, corresponding to a PE ratio of 16 times [2][3]. Summary by Sections Financial Performance - Q3 2024 revenue was 74.23 billion CNY, showing a 1.45% year-on-year increase. The net profit was 6.17 billion CNY, up 6.63% year-on-year, while the net profit margin improved to 5.93% [2]. - The company’s gross margin was reported at 25.53%, a decrease of 2.78 percentage points, while the net profit margin increased by 0.58 percentage points [2]. Future Projections - The report projects revenue growth for 2024E at 10,227 million CNY, with a year-on-year growth rate of 2.1%. The net profit for 2024E is expected to be 708 million CNY, reflecting an 8.3% increase [3]. - The estimated earnings per share (EPS) for 2024E is 1.17 CNY, with projections of 1.37 CNY for 2025E and 1.70 CNY for 2026E [3]. Valuation Metrics - The report assigns a PE ratio of 16 for the current valuation, with a target price of 22 CNY based on the expected growth in net profit and earnings per share [2][3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported Q3 results that met expectations, with a focus on benefiting from equipment upgrades [1][5] - The company achieved operating revenue of 74.23 billion yuan in the first three quarters, a year-on-year increase of 1.45%, and a net profit attributable to shareholders of 6.17 billion yuan, up 6.63% year-on-year [3][4] - The report highlights the company's strategy of focusing on "medical devices and pharmaceutical equipment," maintaining cost control and structural adjustments [4] Summary by Sections Financial Performance - In Q3, the company recorded operating revenue of 22.37 billion yuan, a slight decrease of 0.32% year-on-year, while net profit increased by 10.65% to 1.33 billion yuan [3][4] - The gross profit margin and net profit margin for the first three quarters were 26.31% and 8.54%, respectively, with a slight year-on-year decline in gross margin due to industry pressures [4] Market Outlook - The report anticipates that the implementation of the "large-scale equipment update and consumer goods replacement" policy will lead to increased revenue and profit for the company in Q4 2024 and Q1 2025 [5][6] - The company is expected to benefit from the recovery of procurement demand in public medical institutions, which have accumulated unmet procurement needs [5] Earnings Forecast - The company is projected to achieve operating revenues of 106 billion yuan, 113 billion yuan, and 120 billion yuan for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 5.4%, 7.1%, and 6.4% [6][8] - Net profit attributable to shareholders is expected to reach 7.7 billion yuan, 8.6 billion yuan, and 9.5 billion yuan for the same years, reflecting growth rates of 17.5%, 12.4%, and 9.7% [6][8]

证券代码：600587 证券简称：新华医疗 公告编号：临 2024-038 山东新华医疗器械股份有限公司 1、产品名称：鼻窦镜 2、注册证编号：鲁械注准 20242060939 3、注册人名称：新华手术器械有限公司 4、注册人住所：淄博高新区泰美路 7 号 5、生产地址：淄博高新区泰美路 7 号 关于子公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）子公 司新华手术器械有限公司于近日收到山东省药品监督管理局颁发的《中华人民共 和国医疗器械注册证》，具体情况如下： 一、医疗器械注册证的具体情况 M 型：175Φ2.7,0°、175Φ2.7,30°、175Φ4,0°、175Φ4,30°、175Φ 4,70° 8、适用范围：用于在鼻窦观察成像。 9、批准日期：2024 年 10 月 20 日 10、有效期至：2029 年 10 月 19 日 11、同类产品相关情况：根据国家药品监督管理局官网数据查询信息，截至 目前，国内同行业有 ...

Financial Performance - The company's operating revenue for Q3 2024 was CNY 2,236,724,325.90, a decrease of 0.32% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2024 was CNY 132,739,308.31, an increase of 10.65% year-over-year[2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for the year-to-date was CNY 607,069,625.40, reflecting a 9.36% increase compared to the previous year[6]. - The basic earnings per share for Q3 2024 was CNY 0.18, down 30.77% from the same period last year[3]. - Total operating revenue for the first three quarters of 2024 reached ¥7,423,276,804.99, an increase from ¥7,316,820,996.26 in the same period of 2023, representing a growth of approximately 1.46%[16]. - Net profit for the first three quarters of 2024 was ¥633,953,374.65, up from ¥605,785,162.05 in 2023, reflecting a growth of approximately 4.73%[18]. - Total comprehensive income for the period reached CNY 634,016,268.78, an increase from CNY 605,785,162.05 in the previous year[19]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 15,389,220,215.01, a decrease of 1.29% from the end of the previous year[3]. - The company's total assets as of the end of the third quarter of 2024 were ¥15,389,220,215.01, a decrease from ¥15,590,329,775.23 at the end of the previous quarter[14]. - The total liabilities decreased to ¥7,486,663,182.91 from ¥7,870,494,104.65, showing a reduction of about 4.87%[14]. - The total equity attributable to shareholders at the end of the reporting period was CNY 7,485,939,780.05, an increase of 2.29% from the previous year[3]. - The equity attributable to shareholders of the parent company increased to ¥7,485,939,780.05 from ¥7,318,625,200.44, marking an increase of approximately 2.28%[15]. Cash Flow - The cash flow from operating activities for the year-to-date was CNY -36,159,027.91, a significant decrease of 112.56% compared to the previous year[6]. - Cash inflow from operating activities totaled CNY 7,182,115,065.89, down from CNY 7,667,040,813.17 year-over-year[20]. - Cash outflow for operating activities was CNY 7,218,274,093.80, compared to CNY 7,379,098,391.22 in the previous year[21]. - Net cash flow from investing activities was CNY -263,629,923.83, an improvement from CNY -436,548,699.42 in the previous year[21]. - Cash flow from financing activities resulted in a net outflow of CNY -392,846,564.74, compared to a net inflow of CNY 940,311,207.02 in the same period last year[21]. - The ending balance of cash and cash equivalents was CNY 2,348,299,423.67, up from CNY 2,250,312,516.61 year-over-year[21]. - The company received CNY 774,990,000.00 in borrowings during the period, down from CNY 862,440,000.00 in the previous year[21]. Operational Metrics - The weighted average return on equity for Q3 2024 was 1.83%, an increase of 0.19 percentage points compared to the previous quarter[3]. - Research and development expenses for the first three quarters of 2024 were ¥297,141,310.80, compared to ¥291,314,885.11 in 2023, indicating an increase of about 2.00%[18]. - The company reported a decrease in management expenses to ¥301,150,902.47 from ¥351,188,573.97, reflecting a reduction of approximately 14.26%[18]. - The company experienced a decline in cash received from sales of goods and services, impacting the cash flow from operating activities negatively[6]. - The company reported a decrease in revenue from sales of goods and services to CNY 6,962,340,927.85, compared to CNY 7,428,162,090.93 in the same period last year[20]. Asset Composition - Total current assets as of September 30, 2024, amounted to ¥9,367,034,360.25, a decrease from ¥9,454,331,945.33 at the end of 2023, reflecting a decline of approximately 0.92%[12]. - Cash and cash equivalents decreased to ¥2,474,624,687.68 from ¥3,188,296,441.67, representing a decline of about 22.3%[12]. - Accounts receivable increased to ¥2,031,717,938.62 from ¥1,694,832,478.74, marking an increase of approximately 19.9%[13]. - Inventory decreased to ¥3,441,900,783.28 from ¥3,555,786,774.42, indicating a decline of about 3.2%[13]. - Long-term equity investments decreased to ¥1,488,841,800.85 from ¥1,633,724,381.31, reflecting a decline of approximately 8.8%[13]. - Non-current assets totaled ¥6,022,185,854.76, down from ¥6,135,997,829.90, indicating a decrease of about 1.85%[13]. - The company reported a significant increase in other receivables, which rose to ¥605,410,991.25 from ¥238,494,581.70, an increase of approximately 153.5%[13]. Legal and Regulatory - The company reached a settlement with 3M Innovation Co., Ltd., agreeing to pay a settlement amount of ¥20 million related to patent disputes[11]. - The company has not disclosed any related party relationships among the top ten shareholders[10]. - There were no changes in the participation of major shareholders in margin trading and securities lending activities compared to the previous period[10]. Future Outlook - Future outlook includes continued focus on market expansion and potential new product development, although specific figures were not disclosed in the report[18].

证券代码：600587 证券简称：新华医疗 公告编号：临2024-037 山东新华医疗器械股份有限公司 股权激励限制性股票回购注销实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 回购注销原因：根据公司《2021 年限制性股票激励计划（草案）》（以下 简称"《激励计划》"）的相关规定，原授予限制性股票的激励对象崔权离职， 不再符合激励条件，公司拟对该激励对象已获授但尚未解除限售的限制性股票合 计 8,667 股进行回购并注销。 本次注销股份的有关情况 本次回购注销限制性股票涉及崔权 1 人，合计拟回购注销限制性股票 8,667 股，公司已足额支付股份回购款项；本次回购注销完成后，剩余股权激励限制性 股票 463.1427 万股。 | 回购股份数量（股） | 注销股份数量（股） | 注销日期 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 8,667 | 8,667 | 2024 | 年 | 10 | 月 | 25 | ...

北京市东城区 北三环东路 36 号环球贸易中 心 B 座 11 层 电话（Tel）： 52213236/7 邮编（P.C）： 100013 关 于 山 东 新 华 医 疗 器 械 股 份 有 限 公 司 回 购 注 销 2021 年 限 制 性 股 票 激 励 计 划 部 分 限 制 性 股 票 及 调 整 回 购 价 格 之 法 律 意 见 书 北 京 市 君 致 律 师 事 务 所 北京市东城区北三环东路 36 号环球贸易中心 B 座 11 层 邮编(100013) Add: 11/F, Tower B, Global Trade Center, No.36 North Third Ring Road East, Dongcheng District, Beijing, 100013, PRC Tel: 010-52213236/7 www.junzhilawyer.com 君致（ 法 ）字[2024]373 号 1 北京市君致律师事务所 关于山东新华医疗器械股份有限公司 回购注销 2021 年限制性股票激励计划部分限制性股票 及调整回购价格之法律意见书 君致法字 2024373 号 致：山东新华医疗器械 ...

证券代码：600587 证券简称：新华医疗 公告编号：临 2024-036 山东新华医疗器械股份有限公司 关于公司产品获得二类医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）于近 日收到山东省药品监督管理局颁发的《中华人民共和国医疗器械注册证》，具体 情况如下： 型号：C、D 规格：尺寸：16×16、20×20、25×26.5、25×50、25×60、98×10、98× 12、98×14、98×16、98×18、98×20、98×22、98×25、98×30 颜色：A1，A2，A3，A3.5，A4，B1，B2，B3，B4，C1，C2，C3，C4，D2， D3，D4，1M1，1M2，2L1.5，2L2.5，2M1，2M2，2M3，2R1.5，2R2.5，3L1.5， 3L2.5，3M1，3M2，3M3，3R1.5，3R2.5，4L1.5，4L2.5，4M1，4M2，4M3， 4R1.5，4R2.5，5M1，5M2，5M3，0M1,0M2,0 ...